M. Dain

C. Cooper, P. Delmas, J. Stakkestad, 1999, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

PDB79 DURATION OF FIRST INSULIN THERAPY IN PREVIOUSLY UNCONTROLLED TYPE 2 DIABETES: COMPARISON OF INSULINS GLARGINE, DETEMIR AND NPH AND ASSOCIATION WITH GLYCEMIC CONTROL

P. Home, A. McMahon, G. Hall, 2010 .

Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System

A. Renoux, M. Douin, M. Dain, 1995, Clinical drug investigation.

Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) – a proof-of-concept study

C. Kapitza, K. Rave, M. Nauck, 2010 .

Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism

M. Dain, A. Clarke, 2006, Expert opinion on drug delivery.

Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol

A. Gauthier, D. Upmalis, M. Dain, 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.

Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Facility-Level ART Unit Cost Analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia

Crispin Moyo, Parul Batra, Yogan Pillay, 2014, PloS one.

Antiretroviral Procurement and Supply Chain Management

M. Dain, David Ripin, David Jamieson, 2014, Antiviral therapy.

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin

C. Kapitza, K. Rave, M. Nauck, 2010, Diabetes Care.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes

C. Mathieu, M. Riddle, G. Bolli, 2014, Diabetes, obesity & metabolism.

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.

N. Freemantle, B. Balkau, W. Scherbaum, 2015, Diabetes research and clinical practice.

Do physicians understand Type 2 diabetes patients' perceptions of seriousness; the emotional impact and needs for care improvement? A cross-national survey.

W. Polonsky, J. Twisk, T. Hajós, 2011, Patient education and counseling.

Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.

D. Owens, P. Mullins, S. Del Prato, 2016, Primary care diabetes.

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

D. Owens, W. Landgraf, M. Dain, 2014, Diabetes research and clinical practice.

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

P. de Pablos-Velasco, H. Yki-Järvinen, B. Charbonnel, 2015, Diabetes, obesity & metabolism.

Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women ☆ ☆☆

D. Felsenberg, P. Delmas, J. Stakkestad, 2001 .

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.

D. Archer, D. Tipping, M. Dain, 1999, Obstetrics and gynecology.

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study

M. Shestakova, S. Jacqueminet, A. Grímaldi, 2009, Diabetes, obesity & metabolism.

Clinical experience with insulin glargine in type 1 diabetes.

S. Garg, M. Dain, E. Moser, 2010, Diabetes technology & therapeutics.

A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

H. Gerstein, A. Pfeiffer, J. DeVries, 2010, Diabetes Care.

Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial

J. Rosenstock, P. Mullins, M. Riddle, 2014, Journal of diabetes and its complications.

A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.

R. Bergenstal, J. DeVries, A. Barnett, 2014, European endocrinology.

A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes.

P. Home, A. McMahon, G. Hall, 2011, Diabetes research and clinical practice.

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

N. Freemantle, B. Balkau, W. Scherbaum, 2013 .

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs

H. Gerstein, A. Pfeiffer, J. DeVries, 2010 .